Avantor Key Executives
This section highlights Avantor's key executives, including their titles and compensation details.
Find Contacts at Avantor
(Showing 0 of )
Avantor Earnings
This section highlights Avantor's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-07 | $0.25 | $0.27 |
| Read Transcript | Q3 | 2024 | 2024-10-25 | $0.25 | $0.26 |
| Read Transcript | Q2 | 2024 | 2024-07-26 | $0.23 | $0.25 |
| Read Transcript | Q1 | 2024 | 2024-04-26 | $0.20 | $0.22 |
| Read Transcript | Q4 | 2023 | 2024-02-14 | $0.22 | $0.25 |
| Read Transcript | Q3 | 2023 | 2023-10-27 | $0.25 | $0.25 |
| Read Transcript | Q2 | 2023 | 2023-07-28 | $0.29 | $0.28 |
| Read Transcript | Q1 | 2023 | 2023-04-28 | $0.28 | $0.29 |
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
$15.10
Stock Price
$10.29B
Market Cap
13.50K
Employees
Radnor, PA
Location
Financial Statements
Access annual & quarterly financial statements for Avantor, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $6.78B | $6.97B | $7.51B | $7.39B | $6.39B |
| Cost of Revenue | $4.50B | $4.60B | $4.91B | $4.88B | $4.31B |
| Gross Profit | $2.28B | $2.36B | $2.60B | $2.50B | $2.08B |
| Gross Profit Ratio | 33.60% | 33.93% | 34.65% | 33.88% | 32.54% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $1.37B |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.64B | $1.51B | $1.47B | $1.53B | $1.37B |
| Other Expenses | $-446.60M | $- | $-800.00K | $10.60M | $9.90M |
| Operating Expenses | $1.19B | $1.66B | $1.47B | $1.53B | $1.37B |
| Cost and Expenses | $5.70B | $6.26B | $6.38B | $6.41B | $5.69B |
| Interest Income | $- | $- | $265.80M | $229.30M | $307.60M |
| Interest Expense | $218.80M | $284.80M | $265.80M | $217.40M | $307.60M |
| Depreciation and Amortization | $12.10M | $402.30M | $405.50M | $379.20M | $395.40M |
| EBITDA | $1.08B | $1.13B | $1.53B | $1.35B | $765.30M |
| EBITDA Ratio | 15.99% | 16.19% | 20.37% | 18.27% | 11.97% |
| Operating Income | $1.08B | $696.40M | $1.13B | $972.20M | $706.80M |
| Operating Income Ratio | 15.99% | 10.00% | 15.04% | 13.16% | 11.05% |
| Total Other Income Expenses Net | $-230.90M | $-285.90M | $-279.10M | $-219.20M | $-644.50M |
| Income Before Tax | $853.90M | $410.50M | $851.10M | $753.00M | $62.30M |
| Income Before Tax Ratio | 12.59% | 5.89% | 11.33% | 10.19% | 0.97% |
| Income Tax Expense | $142.40M | $89.40M | $164.60M | $180.40M | $-54.30M |
| Net Income | $711.50M | $321.10M | $686.50M | $572.60M | $116.60M |
| Net Income Ratio | 10.49% | 4.61% | 9.14% | 7.75% | 1.82% |
| EPS | $1.05 | $0.48 | $1.02 | $0.86 | $0.20 |
| EPS Diluted | $1.04 | $0.47 | $1.01 | $0.85 | $0.20 |
| Weighted Average Shares Outstanding | 680.30M | 675.60M | 650.90M | 590.50M | 576.30M |
| Weighted Average Shares Outstanding Diluted | 681.90M | 678.40M | 679.40M | 599.60M | 583.40M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.69B | $1.71B | $1.70B | $1.68B | $1.72B | $1.72B | $1.74B | $1.78B | $1.79B | $1.86B | $1.91B | $1.95B | $1.91B | $1.83B | $1.86B | $1.79B | $1.79B | $1.60B | $1.48B | $1.52B |
| Cost of Revenue | $1.12B | $1.15B | $1.12B | $1.11B | $1.15B | $1.14B | $1.15B | $1.16B | $1.18B | $1.21B | $1.26B | $1.26B | $1.26B | $1.22B | $1.23B | $1.17B | $1.21B | $1.10B | $988.10M | $1.02B |
| Gross Profit | $562.90M | $564.40M | $581.50M | $570.50M | $570.40M | $578.60M | $590.00M | $624.80M | $614.50M | $650.70M | $647.70M | $689.90M | $647.50M | $615.90M | $626.50M | $612.80M | $581.60M | $506.40M | $490.60M | $501.90M |
| Gross Profit Ratio | 33.37% | 32.92% | 34.15% | 33.96% | 33.11% | 33.64% | 33.83% | 35.10% | 34.23% | 35.05% | 33.90% | 35.37% | 33.94% | 33.58% | 33.71% | 34.32% | 32.48% | 31.55% | 33.18% | 33.04% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $352.10M | $- | $352.10M | $- | $371.80M | $- | $371.80M | $- | $377.00M | $- | $- | $343.50M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $10.60M | $- | $- | $- | $61.70M | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $371.40M | $439.80M | $396.00M | $401.00M | $387.10M | $368.40M | $357.50M | $393.60M | $362.70M | $374.90M | $352.10M | $382.90M | $433.50M | $378.70M | $371.80M | $346.50M | $377.00M | $329.20M | $324.00M | $343.50M |
| Other Expenses | $-446.60M | $- | $600.00K | $300.00K | $1.70M | $700.00K | $2.00M | $600.00K | $-5.60M | $2.70M | $1.60M | $1.40M | $-9.20M | $3.40M | $14.60M | $2.60M | $-1.70M | $2.50M | $2.40M | $2.40M |
| Operating Expenses | $-75.20M | $390.40M | $396.00M | $401.00M | $387.10M | $368.40M | $357.50M | $393.60M | $362.70M | $374.90M | $352.10M | $382.90M | $433.50M | $378.70M | $371.80M | $346.50M | $377.00M | $329.20M | $324.00M | $343.50M |
| Cost and Expenses | $1.05B | $1.54B | $1.52B | $1.51B | $1.54B | $1.51B | $1.51B | $1.55B | $1.54B | $1.58B | $1.61B | $1.64B | $1.69B | $1.60B | $1.60B | $1.52B | $1.59B | $1.43B | $1.31B | $1.36B |
| Interest Income | $- | $- | $- | $- | $- | $72.40M | $73.40M | $73.70M | $69.80M | $67.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $44.90M | $48.70M | $60.90M | $64.30M | $65.30M | $72.40M | $73.40M | $73.70M | $69.80M | $67.30M | $63.90M | $64.80M | $60.80M | $54.10M | $51.00M | $51.50M | $55.80M | $65.20M | $92.10M | $94.50M |
| Depreciation and Amortization | $100.90M | $102.40M | $102.60M | $99.60M | $100.60M | $98.00M | $102.60M | $101.10M | $100.70M | $100.60M | $89.70M | $114.50M | $104.10M | $100.00M | $86.10M | $89.00M | $102.00M | $99.10M | $97.80M | $96.50M |
| EBITDA | $730.00M | $225.60M | $304.50M | $270.90M | $293.90M | $315.30M | $182.30M | $336.90M | $350.20M | $376.20M | $379.90M | $421.10M | $304.90M | $340.60M | $352.20M | $351.90M | $184.50M | $56.50M | $268.60M | $255.70M |
| EBITDA Ratio | 43.28% | 13.16% | 17.88% | 16.13% | 17.06% | 18.33% | 10.45% | 18.92% | 19.51% | 20.26% | 19.88% | 21.59% | 15.98% | 18.57% | 18.95% | 19.71% | 10.30% | 3.52% | 18.16% | 16.83% |
| Operating Income | $638.10M | $124.60M | $185.50M | $169.50M | $183.30M | $210.20M | $71.70M | $231.20M | $251.80M | $275.80M | $295.60M | $307.00M | $214.00M | $237.20M | $254.70M | $266.30M | $204.60M | $177.20M | $166.60M | $158.40M |
| Operating Income Ratio | 37.83% | 7.27% | 10.89% | 10.09% | 10.64% | 12.22% | 4.11% | 12.99% | 14.03% | 14.86% | 15.47% | 15.74% | 11.22% | 12.93% | 13.70% | 14.91% | 11.42% | 11.04% | 11.27% | 10.43% |
| Total Other Income Expenses Net | $-85.50M | $-50.10M | $-70.90M | $-88.90M | $-63.80M | $-73.70M | $-73.00M | $-75.40M | $-77.10M | $-67.50M | $-69.30M | $-65.20M | $-74.00M | $-50.70M | $-39.60M | $-54.90M | $-177.90M | $-285.00M | $-87.90M | $-93.70M |
| Income Before Tax | $552.60M | $74.50M | $114.60M | $80.60M | $119.50M | $136.50M | $-1.30M | $155.80M | $174.70M | $208.30M | $226.30M | $241.80M | $140.00M | $186.50M | $215.10M | $211.40M | $26.70M | $-107.80M | $78.70M | $64.70M |
| Income Before Tax Ratio | 32.76% | 4.35% | 6.73% | 4.80% | 6.94% | 7.94% | -0.07% | 8.75% | 9.73% | 11.22% | 11.85% | 12.40% | 7.34% | 10.17% | 11.57% | 11.84% | 1.49% | -6.72% | 5.32% | 4.26% |
| Income Tax Expense | $52.20M | $16.70M | $21.70M | $20.20M | $21.00M | $28.10M | $6.00M | $34.30M | $33.00M | $41.30M | $38.90M | $51.40M | $46.00M | $29.70M | $57.30M | $47.40M | $-24.90M | $-65.60M | $18.50M | $17.70M |
| Net Income | $500.40M | $57.80M | $92.90M | $60.40M | $98.50M | $108.40M | $-7.30M | $121.50M | $141.70M | $167.00M | $187.40M | $190.40M | $94.00M | $156.80M | $157.80M | $164.00M | $51.60M | $-42.20M | $60.20M | $47.00M |
| Net Income Ratio | 29.67% | 3.37% | 5.46% | 3.60% | 5.72% | 6.30% | -0.42% | 6.82% | 7.89% | 9.00% | 9.81% | 9.76% | 4.93% | 8.55% | 8.49% | 9.18% | 2.88% | -2.63% | 4.07% | 3.09% |
| EPS | $0.74 | $0.09 | $0.14 | $0.09 | $0.15 | $0.16 | $-0.01 | $0.18 | $0.21 | $0.25 | $0.29 | $0.28 | $0.13 | $0.24 | $0.24 | $0.25 | $0.06 | $-0.07 | $0.08 | $0.05 |
| EPS Diluted | $0.73 | $0.08 | $0.14 | $0.09 | $0.14 | $0.16 | $-0.01 | $0.18 | $0.21 | $0.25 | $0.28 | $0.28 | $0.13 | $0.24 | $0.24 | $0.25 | $0.06 | $-0.07 | $0.08 | $0.05 |
| Weighted Average Shares Outstanding | 680.70M | 680.30M | 679.40M | 678.10M | 676.40M | 676.00M | 675.30M | 674.70M | 674.20M | 674.10M | 650.80M | 681.30M | 609.50M | 588.50M | 582.60M | 581.10M | 578.70M | 577.20M | 575.60M | 573.70M |
| Weighted Average Shares Outstanding Diluted | 682.70M | 683.00M | 682.60M | 681.40M | 679.20M | 678.50M | 675.30M | 678.10M | 677.10M | 679.30M | 680.20M | 681.30M | 619.00M | 598.10M | 591.10M | 589.10M | 587.10M | 577.20M | 582.10M | 581.30M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $261.90M | $262.90M | $372.90M | $301.70M | $286.60M |
| Short Term Investments | $- | $16.60M | $26.20M | $- | $- |
| Cash and Short Term Investments | $261.90M | $262.90M | $372.90M | $301.70M | $286.60M |
| Net Receivables | $1.03B | $1.15B | $1.22B | $1.22B | $1.11B |
| Inventory | $731.50M | $828.10M | $913.50M | $872.00M | $739.60M |
| Other Current Assets | $118.70M | $143.70M | $153.10M | $81.40M | $91.40M |
| Total Current Assets | $2.15B | $2.38B | $2.66B | $2.48B | $2.23B |
| Property Plant Equipment Net | $708.10M | $858.20M | $727.00M | $705.50M | $549.90M |
| Goodwill | $5.54B | $5.72B | $5.65B | $5.34B | $2.86B |
| Intangible Assets | $3.36B | $3.78B | $4.13B | $5.14B | $4.05B |
| Goodwill and Intangible Assets | $8.90B | $9.49B | $9.79B | $10.48B | $6.91B |
| Long Term Investments | $- | $50.10M | $66.70M | $25.40M | $-723.90M |
| Tax Assets | $- | $-50.10M | $-66.70M | $-25.40M | $723.90M |
| Other Non-Current Assets | $360.40M | $187.50M | $293.50M | $233.10M | $216.70M |
| Total Non-Current Assets | $9.97B | $10.59B | $10.81B | $11.42B | $7.68B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $12.11B | $12.97B | $13.46B | $13.90B | $9.91B |
| Account Payables | $662.80M | $625.90M | $758.20M | $755.10M | $678.90M |
| Short Term Debt | $821.10M | $259.90M | $364.20M | $45.20M | $26.40M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $731.40M | $249.50M | $223.80M |
| Other Current Liabilities | $523.60M | $594.50M | $536.40M | $650.50M | $537.40M |
| Total Current Liabilities | $2.01B | $1.48B | $1.66B | $1.45B | $1.24B |
| Long Term Debt | $- | $5.28B | $6.07B | $7.20B | $5.13B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $557.30M | $612.80M | $731.40M | $913.00M | $723.90M |
| Other Non-Current Liabilities | $3.59B | $350.30M | $144.10M | $134.20M | $133.80M |
| Total Non-Current Liabilities | $4.15B | $6.24B | $6.95B | $8.25B | $5.99B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $6.16B | $7.72B | $8.61B | $9.70B | $7.23B |
| Preferred Stock | $- | $- | $- | $1.00B | $1.00B |
| Common Stock | $3.94B | $3.83B | $3.79B | $2.75B | $1.74B |
| Retained Earnings | $- | $1.49B | $1.17B | $483.90M | $-88.70M |
| Accumulated Other Comprehensive Income Loss | $-184.00M | $-69.00M | $-100.30M | $-43.20M | $21.70M |
| Other Total Stockholders Equity | $2.20B | $- | $- | $- | $- |
| Total Stockholders Equity | $5.96B | $5.25B | $4.86B | $4.20B | $2.67B |
| Total Equity | $5.96B | $5.25B | $4.86B | $4.20B | $2.67B |
| Total Liabilities and Stockholders Equity | $12.11B | $12.97B | $13.46B | $13.90B | $9.91B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.11B | $12.97B | $13.46B | $13.90B | $9.91B |
| Total Investments | $- | $66.70M | $66.70M | $25.40M | $-723.90M |
| Total Debt | $821.10M | $5.54B | $6.29B | $7.02B | $4.89B |
| Net Debt | $559.20M | $5.27B | $5.91B | $6.72B | $4.61B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $261.90M | $285.30M | $272.60M | $234.90M | $262.90M | $236.90M | $236.40M | $294.60M | $372.90M | $265.60M | $237.50M | $283.60M | $301.70M | $1.43B | $223.00M | $172.50M | $286.60M | $370.50M | $415.30M | $346.30M |
| Short Term Investments | $- | $- | $14.90M | $18.00M | $16.60M | $28.50M | $28.80M | $19.70M | $26.20M | $25.60M | $5.10M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $261.90M | $285.30M | $272.60M | $234.90M | $262.90M | $236.90M | $236.40M | $294.60M | $372.90M | $265.60M | $237.50M | $283.60M | $301.70M | $1.43B | $223.00M | $172.50M | $286.60M | $370.50M | $415.30M | $346.30M |
| Net Receivables | $1.03B | $1.09B | $1.13B | $1.13B | $1.15B | $1.15B | $1.22B | $1.28B | $1.22B | $1.23B | $1.27B | $1.35B | $1.22B | $1.18B | $1.27B | $1.20B | $1.11B | $1.04B | $983.70M | $1.04B |
| Inventory | $731.50M | $779.60M | $795.60M | $810.60M | $828.10M | $850.30M | $890.40M | $904.00M | $913.50M | $905.00M | $922.50M | $896.00M | $872.00M | $844.00M | $840.90M | $777.70M | $739.60M | $729.80M | $737.80M | $686.10M |
| Other Current Assets | $118.70M | $352.10M | $132.00M | $145.90M | $127.10M | $147.30M | $156.30M | $151.50M | $153.10M | $158.10M | $141.90M | $81.30M | $81.40M | $109.80M | $90.00M | $80.30M | $91.40M | $159.60M | $155.50M | $123.10M |
| Total Current Assets | $2.15B | $2.50B | $2.33B | $2.32B | $2.38B | $2.38B | $2.50B | $2.63B | $2.66B | $2.56B | $2.57B | $2.61B | $2.48B | $3.56B | $2.42B | $2.23B | $2.23B | $2.30B | $2.29B | $2.20B |
| Property Plant Equipment Net | $708.10M | $722.80M | $753.80M | $739.70M | $737.50M | $698.30M | $698.20M | $736.50M | $727.00M | $698.20M | $698.10M | $699.90M | $705.50M | $682.70M | $652.60M | $537.40M | $549.90M | $552.50M | $551.80M | $556.00M |
| Goodwill | $5.54B | $5.67B | $5.66B | $5.67B | $5.72B | $5.64B | $5.69B | $5.68B | $5.65B | $5.51B | $5.63B | $5.27B | $5.34B | $3.51B | $3.56B | $2.82B | $2.86B | $2.81B | $2.76B | $2.74B |
| Intangible Assets | $3.36B | $3.52B | $3.58B | $3.66B | $3.78B | $3.79B | $3.90B | $4.08B | $4.13B | $4.10B | $4.28B | $5.01B | $5.14B | $4.21B | $4.37B | $3.93B | $4.05B | $4.04B | $4.06B | $4.10B |
| Goodwill and Intangible Assets | $8.90B | $9.19B | $9.24B | $9.33B | $9.49B | $9.43B | $9.59B | $9.76B | $9.79B | $9.61B | $9.91B | $10.28B | $10.48B | $7.71B | $7.93B | $6.75B | $6.91B | $6.85B | $6.82B | $6.83B |
| Long Term Investments | $- | $25.00M | $24.10M | $24.30M | $66.70M | $-648.80M | $-662.80M | $24.30M | $24.00M | $22.20M | $23.50M | $-854.40M | $25.40M | $-821.50M | $-863.00M | $-713.00M | $- | $-760.70M | $-788.00M | $-767.40M |
| Tax Assets | $- | $- | $575.40M | $600.60M | $-66.70M | $648.80M | $662.80M | $695.70M | $-24.00M | $728.40M | $745.80M | $854.40M | $-25.40M | $821.50M | $863.00M | $713.00M | $- | $760.70M | $788.00M | $767.40M |
| Other Non-Current Assets | $360.40M | $394.80M | $-231.40M | $-257.20M | $358.30M | $289.20M | $276.70M | $-447.50M | $293.50M | $-506.00M | $-514.50M | $252.00M | $207.70M | $240.00M | $244.60M | $217.10M | $216.70M | $238.60M | $204.00M | $199.50M |
| Total Non-Current Assets | $9.97B | $10.34B | $10.36B | $10.44B | $10.59B | $10.41B | $10.56B | $10.77B | $10.81B | $10.55B | $10.86B | $11.23B | $11.42B | $8.63B | $8.83B | $7.51B | $7.68B | $7.64B | $7.57B | $7.59B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $- |
| Total Assets | $12.11B | $12.84B | $12.69B | $12.76B | $12.97B | $12.80B | $13.06B | $13.40B | $13.46B | $13.11B | $13.43B | $13.84B | $13.90B | $12.20B | $11.25B | $9.74B | $9.91B | $9.94B | $9.87B | $9.79B |
| Account Payables | $662.80M | $673.50M | $657.40M | $573.40M | $625.90M | $655.80M | $686.60M | $765.70M | $758.20M | $768.90M | $798.60M | $818.20M | $755.10M | $698.80M | $755.30M | $706.40M | $678.90M | $625.30M | $581.00M | $610.90M |
| Short Term Debt | $821.10M | $229.70M | $258.40M | $299.10M | $259.90M | $335.60M | $314.00M | $325.20M | $364.20M | $280.60M | $246.40M | $44.70M | $45.20M | $37.00M | $39.50M | $26.50M | $26.40M | $14.40M | $14.30M | $14.30M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $1 | $- | $183.30M | $159.60M | $173.60M | $- | $731.40M | $728.40M | $745.80M | $- | $913.00M | $203.80M | $192.00M | $167.60M | $723.90M | $193.90M | $190.50M | $249.00M |
| Other Current Liabilities | $523.60M | $726.60M | $548.80M | $569.40M | $594.50M | $496.70M | $549.50M | $578.60M | $536.40M | $502.40M | $526.30M | $584.20M | $650.50M | $584.30M | $582.90M | $507.80M | $537.40M | $496.30M | $458.40M | $501.40M |
| Total Current Liabilities | $2.01B | $1.63B | $1.46B | $1.44B | $1.48B | $1.49B | $1.55B | $1.67B | $1.66B | $1.55B | $1.57B | $1.45B | $1.45B | $1.32B | $1.38B | $1.24B | $1.24B | $1.14B | $1.05B | $1.13B |
| Long Term Debt | $- | $4.69B | $4.86B | $5.02B | $5.52B | $5.29B | $5.57B | $5.74B | $6.07B | $5.91B | $6.29B | $6.82B | $7.20B | $5.55B | $5.61B | $4.68B | $5.13B | $5.13B | $5.06B | $5.11B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $557.30M | $547.30M | $575.40M | $600.60M | $612.80M | $648.80M | $662.80M | $695.70M | $731.40M | $728.40M | $745.80M | $854.40M | $913.00M | $821.50M | $863.00M | $713.00M | $723.90M | $760.70M | $788.00M | $767.40M |
| Other Non-Current Liabilities | $3.59B | $418.90M | $361.90M | $360.70M | $110.50M | $271.30M | $268.80M | $300.10M | $144.10M | $334.10M | $351.60M | $361.10M | $134.20M | $403.00M | $411.60M | $301.00M | $133.80M | $361.90M | $420.70M | $339.80M |
| Total Non-Current Liabilities | $4.15B | $5.66B | $5.79B | $5.99B | $6.24B | $6.21B | $6.50B | $6.73B | $6.95B | $6.97B | $7.39B | $8.03B | $8.25B | $6.77B | $6.89B | $5.69B | $5.99B | $6.25B | $6.27B | $6.22B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $6.16B | $7.29B | $7.26B | $7.43B | $7.72B | $7.70B | $8.05B | $8.40B | $8.61B | $8.52B | $8.96B | $9.48B | $9.70B | $8.09B | $8.26B | $6.93B | $7.23B | $7.39B | $7.33B | $7.35B |
| Preferred Stock | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $1.00B | $1.00B | $1.00B | $1.00B | $1.00B | $1.00B | $1.00B | $1.00B | $1.00B |
| Common Stock | $3.94B | $3.92B | $3.90B | $3.88B | $3.83B | $3.82B | $3.80B | $3.79B | $3.79B | $3.77B | $3.76B | $2.75B | $2.75B | $2.75B | $1.75B | $1.74B | $1.74B | $1.74B | $1.74B | $1.75B |
| Retained Earnings | $- | $1.70B | $1.64B | $1.55B | $1.49B | $1.39B | $1.28B | $1.29B | $1.17B | $1.03B | $861.70M | $674.30M | $483.90M | $389.90M | $233.10M | $75.30M | $-88.70M | $-140.30M | $-98.10M | $-158.30M |
| Accumulated Other Comprehensive Income Loss | $-184.00M | $-73.90M | $-107.30M | $-97.00M | $-69.00M | $-111.10M | $-71.90M | $-89.70M | $-100.30M | $-211.80M | $-148.30M | $-69.30M | $-43.20M | $-38.10M | $1.40M | $-16.10M | $21.70M | $-54.70M | $-108.80M | $-153.30M |
| Other Total Stockholders Equity | $2.20B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Stockholders Equity | $5.96B | $5.55B | $5.43B | $5.34B | $5.25B | $5.10B | $5.01B | $4.99B | $4.86B | $4.59B | $4.47B | $4.36B | $4.20B | $4.10B | $2.99B | $2.81B | $2.67B | $2.55B | $2.54B | $2.44B |
| Total Equity | $5.96B | $5.55B | $5.43B | $5.34B | $5.25B | $5.10B | $5.01B | $4.99B | $4.86B | $4.59B | $4.47B | $4.36B | $4.20B | $4.10B | $2.99B | $2.81B | $2.67B | $2.55B | $2.54B | $2.44B |
| Total Liabilities and Stockholders Equity | $12.11B | $12.84B | $12.69B | $12.76B | $12.97B | $12.80B | $13.06B | $13.40B | $13.46B | $13.11B | $13.43B | $13.84B | $13.90B | $12.20B | $11.25B | $9.74B | $9.91B | $9.94B | $9.87B | $9.79B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.11B | $12.84B | $12.69B | $12.76B | $12.97B | $12.80B | $13.06B | $13.40B | $13.46B | $13.11B | $13.43B | $13.84B | $13.90B | $12.20B | $11.25B | $9.74B | $9.91B | $9.94B | $9.87B | $9.79B |
| Total Investments | $- | $25.00M | $24.10M | $24.30M | $66.70M | $-648.80M | $-662.80M | $24.30M | $24.00M | $22.20M | $23.50M | $-854.40M | $25.40M | $-821.50M | $-863.00M | $-713.00M | $- | $-760.70M | $-788.00M | $-767.40M |
| Total Debt | $821.10M | $4.92B | $5.12B | $5.32B | $5.54B | $5.63B | $5.88B | $6.06B | $6.29B | $6.19B | $6.54B | $6.86B | $7.02B | $5.59B | $5.65B | $4.63B | $4.89B | $5.07B | $5.08B | $5.05B |
| Net Debt | $559.20M | $4.64B | $4.84B | $5.09B | $5.27B | $5.39B | $5.65B | $5.77B | $5.91B | $5.92B | $6.30B | $6.58B | $6.72B | $4.16B | $5.43B | $4.46B | $4.61B | $4.70B | $4.66B | $4.71B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $711.50M | $321.10M | $686.50M | $572.60M | $116.60M |
| Depreciation and Amortization | $405.50M | $402.30M | $405.50M | $379.20M | $395.40M |
| Deferred Income Tax | $-46.90M | $-172.40M | $-69.10M | $-17.70M | $-87.50M |
| Stock Based Compensation | $46.80M | $40.50M | $45.80M | $50.70M | $44.10M |
| Change in Working Capital | $- | $16.60M | $-321.30M | $-114.50M | $19.50M |
| Accounts Receivables | $75.10M | $77.00M | $-45.20M | $-111.80M | $-102.40M |
| Inventory | $-18.50M | $30.30M | $-112.50M | $-129.80M | $-69.70M |
| Accounts Payables | $59.60M | $-139.60M | $15.60M | $64.90M | $110.60M |
| Other Working Capital | $- | $48.90M | $-179.20M | $62.20M | $81.00M |
| Other Non Cash Items | $-276.10M | $261.90M | $96.20M | $83.30M | $441.70M |
| Net Cash Provided by Operating Activities | $840.80M | $870.00M | $843.60M | $953.60M | $929.80M |
| Investments in Property Plant and Equipment | $-148.80M | $-146.40M | $-133.40M | $-111.10M | $-61.60M |
| Acquisitions Net | $- | $- | $-20.20M | $-4.01B | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $42.50M | $- | $- |
| Other Investing Activities | $587.70M | $2.70M | $1.50M | $3.50M | $2.50M |
| Net Cash Used for Investing Activities | $438.90M | $-143.70M | $-109.60M | $-4.12B | $-59.10M |
| Debt Repayment | $-1.34B | $-846.00M | $-620.40M | $2.30B | $-738.50M |
| Common Stock Issued | $- | $- | $- | $967.00M | $20.20M |
| Common Stock Repurchased | $-8.60M | $-13.70M | $-13.20M | $-25.80M | $-20.20M |
| Dividends Paid | $- | $- | $-32.40M | $-64.60M | $-64.60M |
| Other Financing Activities | $69.20M | $16.00M | $17.30M | $41.90M | $20.20M |
| Net Cash Used Provided by Financing Activities | $-1.28B | $-843.70M | $-648.70M | $3.22B | $-782.90M |
| Effect of Forex Changes on Cash | $-21.50M | $8.20M | $-15.50M | $-13.20M | $12.10M |
| Net Change in Cash | $-23.00M | $-109.20M | $69.80M | $37.90M | $99.90M |
| Cash at End of Period | $264.70M | $287.70M | $396.90M | $327.10M | $289.20M |
| Cash at Beginning of Period | $287.70M | $396.90M | $327.10M | $289.20M | $189.30M |
| Operating Cash Flow | $840.80M | $870.00M | $843.60M | $953.60M | $929.80M |
| Capital Expenditure | $-148.80M | $-146.40M | $-133.40M | $-111.10M | $-61.60M |
| Free Cash Flow | $692.00M | $723.60M | $710.20M | $842.50M | $868.20M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $500.40M | $57.80M | $92.90M | $60.40M | $98.50M | $108.40M | $-7.30M | $121.50M | $141.70M | $167.00M | $187.40M | $190.40M | $94.00M | $156.80M | $157.80M | $164.00M | $51.60M | $-42.20M | $60.20M | $47.00M |
| Depreciation and Amortization | $100.90M | $102.40M | $102.60M | $99.60M | $100.60M | $98.00M | $102.60M | $101.10M | $100.70M | $100.60M | $89.70M | $114.50M | $104.10M | $100.00M | $86.10M | $89.00M | $102.00M | $99.10M | $97.80M | $96.50M |
| Deferred Income Tax | $28.40M | $-22.60M | $-34.80M | $-17.90M | $-78.30M | $-29.40M | $-38.30M | $-26.40M | $-7.30M | $-22.30M | $-17.20M | $-22.30M | $6.30M | $-18.70M | $19.50M | $-5.30M | $3.20M | $-68.60M | $-17.90M | $-4.20M |
| Stock Based Compensation | $11.10M | $11.90M | $11.10M | $12.70M | $8.80M | $9.80M | $9.20M | $12.70M | $10.00M | $12.10M | $13.00M | $10.70M | $13.70M | $13.40M | $12.20M | $11.40M | $12.70M | $11.40M | $11.60M | $8.40M |
| Change in Working Capital | $-53.40M | $63.30M | $91.30M | $-48.00M | $97.00M | $22.70M | $-92.20M | $-10.90M | $-64.10M | $-22.00M | $-68.50M | $-166.70M | $64.90M | $-7.50M | $-17.50M | $-154.40M | $-28.80M | $46.10M | $-75.30M | $77.50M |
| Accounts Receivables | $11.70M | $34.20M | $-2.70M | $2.70M | $21.90M | $47.20M | $60.10M | $-52.20M | $53.80M | $-800.00K | $39.10M | $-137.30M | $-45.30M | $55.50M | $-15.20M | $-106.80M | $-51.80M | $-34.50M | $64.00M | $-80.10M |
| Inventory | $3.00M | $10.80M | $-3.20M | $-11.00M | $21.20M | $10.80M | $-8.80M | $7.10M | $1.60M | $-21.00M | $-46.70M | $-46.40M | $-12.00M | $-14.80M | $-48.70M | $-54.30M | $-36.20M | $12.90M | $-51.70M | $5.30M |
| Accounts Payables | $17.70M | $-4.00M | $89.50M | $-43.60M | $-43.80M | $-21.40M | $-75.00M | $600.00K | $-49.50M | $-7.30M | $-800.00K | $73.20M | $63.00M | $-61.20M | $32.80M | $30.30M | $42.80M | $36.70M | $-35.90M | $67.00M |
| Other Working Capital | $-85.80M | $22.30M | $7.70M | $3.90M | $97.70M | $-13.90M | $-68.50M | $33.60M | $-70.00M | $7.10M | $-60.10M | $-56.20M | $59.20M | $13.00M | $13.60M | $-23.60M | $16.40M | $31.00M | $-51.70M | $85.30M |
| Other Non Cash Items | $-414.10M | $32.00M | $150.70M | $298.60M | $25.00M | $21.20M | $194.20M | $21.50M | $24.60M | $22.90M | $23.10M | $25.60M | $18.00M | $17.90M | $5.70M | $22.20M | $165.30M | $235.70M | $12.80M | $27.90M |
| Net Cash Provided by Operating Activities | $173.30M | $244.80M | $281.10M | $141.60M | $251.60M | $230.70M | $168.20M | $219.50M | $205.60M | $258.30M | $227.50M | $152.20M | $301.00M | $261.90M | $263.80M | $126.90M | $306.00M | $281.50M | $89.20M | $253.10M |
| Investments in Property Plant and Equipment | $-27.50M | $-40.80M | $-45.80M | $-34.70M | $-50.60M | $-37.70M | $-30.10M | $-28.00M | $-33.60M | $-39.00M | $-36.30M | $-24.50M | $-40.00M | $-32.60M | $-23.40M | $-15.10M | $-20.20M | $-15.30M | $-13.50M | $-12.60M |
| Acquisitions Net | $- | $- | $- | $- | $-4.90M | $- | $- | $-15.30M | $- | $- | $-4.90M | $-15.30M | $-2.85B | $-2.20M | $-1.17B | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-42.50M | $42.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $586.00M | $300.00K | $900.00K | $500.00K | $5.50M | $700.00K | $700.00K | $16.00M | $43.00M | $600.00K | $100.00K | $300.00K | $1.70M | $500.00K | $800.00K | $500.00K | $1.40M | $-600.00K | $1.00M | $700.00K |
| Net Cash Used for Investing Activities | $558.50M | $-40.50M | $-44.90M | $-34.20M | $-50.00M | $-37.00M | $-29.40M | $-27.30M | $-33.10M | $4.10M | $-41.10M | $-39.50M | $-2.88B | $-34.30M | $-1.19B | $-14.60M | $-18.80M | $-15.90M | $-12.50M | $-11.90M |
| Debt Repayment | $-756.80M | $-214.30M | $-201.60M | $-169.10M | $-188.10M | $-197.60M | $-190.80M | $-269.50M | $-82.40M | $-224.10M | $-202.00M | $-111.90M | $1.49B | $-9.40M | $1.03B | $-208.60M | $-370.60M | $-300.40M | $-3.70M | $-63.80M |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-967.00M | $967.00M | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-400.00K | $-800.00K | $-800.00K | $-6.60M | $-200.00K | $-200.00K | $-5.20M | $-8.10M | $-100.00K | $-100.00K | $-8.10M | $-4.90M | $25.80M | $- | $-9.60M | $-16.20M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $-16.10M | $- | $- | $- | $-32.40M | $- | $-16.30M | $-16.10M | $-16.20M | $-16.10M | $-16.20M | $-16.10M | $-16.20M | $-16.10M | $-16.20M | $-16.10M |
| Other Financing Activities | $1.90M | $16.50M | $5.30M | $45.50M | $4.20M | $9.40M | $-200.00K | $2.60M | $33.30M | $4.80M | $5.90M | $5.70M | $-12.00M | $38.90M | $-2.50M | $19.90M | $6.40M | $400.00K | $6.60M | $6.80M |
| Net Cash Used Provided by Financing Activities | $-755.30M | $-198.60M | $-197.10M | $-130.20M | $-184.10M | $-188.40M | $-196.20M | $-275.00M | $-81.60M | $-219.40M | $-220.50M | $-127.20M | $1.46B | $980.40M | $998.80M | $-221.00M | $-380.40M | $-316.10M | $-13.30M | $-73.10M |
| Effect of Forex Changes on Cash | $-22.10M | $7.90M | $-1.60M | $-5.70M | $9.50M | $-5.40M | $-700.00K | $4.80M | $18.20M | $-16.20M | $-13.30M | $-4.20M | $-3.20M | $-5.50M | $900.00K | $-5.40M | $9.30M | $5.70M | $5.60M | $-8.50M |
| Net Change in Cash | $-45.60M | $13.60M | $37.70M | $-28.00M | $27.00M | $-100.00K | $-58.10M | $-78.00M | $109.10M | $26.80M | $-47.40M | $-18.70M | $-1.12B | $1.20B | $74.20M | $-114.10M | $-83.90M | $-44.80M | $69.00M | $159.60M |
| Cash at End of Period | $264.70M | $310.30M | $272.60M | $234.90M | $287.70M | $260.70M | $260.80M | $318.90M | $396.90M | $287.80M | $261.00M | $308.40M | $327.10M | $1.45B | $249.30M | $175.10M | $289.20M | $373.10M | $417.90M | $348.90M |
| Cash at Beginning of Period | $310.30M | $296.70M | $234.90M | $262.90M | $260.70M | $260.80M | $318.90M | $396.90M | $287.80M | $261.00M | $308.40M | $327.10M | $1.45B | $249.30M | $175.10M | $289.20M | $373.10M | $417.90M | $348.90M | $189.30M |
| Operating Cash Flow | $173.30M | $244.80M | $281.10M | $141.60M | $251.60M | $230.70M | $168.20M | $219.50M | $205.60M | $258.30M | $227.50M | $152.20M | $301.00M | $261.90M | $263.80M | $126.90M | $306.00M | $281.50M | $89.20M | $253.10M |
| Capital Expenditure | $-27.50M | $-40.80M | $-45.80M | $-34.70M | $-50.60M | $-37.70M | $-30.10M | $-28.00M | $-33.60M | $-39.00M | $-36.30M | $-24.50M | $-40.00M | $-32.60M | $-23.40M | $-15.10M | $-20.20M | $-15.30M | $-13.50M | $-12.60M |
| Free Cash Flow | $145.80M | $204.00M | $235.30M | $106.90M | $201.00M | $193.00M | $138.10M | $191.50M | $172.00M | $219.30M | $191.20M | $127.70M | $261.00M | $229.30M | $240.40M | $111.80M | $285.80M | $266.20M | $75.70M | $240.50M |
Avantor Dividends
Explore Avantor's dividend history, including dividend yield, payout ratio, and historical payments.
Avantor News
Read the latest news about Avantor, including recent articles, headlines, and updates.
Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX
Industry leading set of technologies to drive scalability, flexibility, and efficiency in biologics production RADNOR, Pa. , April 1, 2025 /PRNewswire/ -- Avantor®, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals.
Avantor® to Report First Quarter 2025 Earnings on Friday, April 25, 2025
RADNOR, Pa. , March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m.
Avantor® Provides First Look at Recently Completed Hydration Expansion at DCAT Week 2025
Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies RADNOR, Pa. , March 17, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services in the life sciences and advanced technology industries, announces that Ger Brophy, PhD, head of Avantor's Scientific Advisory Board, will present highlights of the recently completed expansion at its flagship European manufacturing site at Drug, Chemical & Associated Technologies Association (DCAT) Week 2025.
Avantor® to Present at TD Cowen's 45th Annual Health Care Conference
RADNOR, Pa. , Feb. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will present at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, at 11:50 a.m.
Silq Technologies Corp. and NuSil Technology LLC Announce Collaboration Agreement to Drive Broad-based Adoption of Silq's Novel Surface Treatment Technology
SUNNY ISLES BEACH, Fla.--(BUSINESS WIRE)--Silq Technologies Corporation, a privately held advanced materials science company, and NuSil Technology LLC, a subsidiary of Avantor Inc., Radnor, Pa. (NYSE: AVTR), and a leading global supplier of high-quality silicones for long-term medical implants, have entered into an agreement to facilitate the utilization of Silq's zwitterionic surface treatment technology on medical devices manufactured with NuSil silicone products. Zwitterion surface technolog.
Avantor, Inc. (AVTR) Q4 2024 Earnings Call Transcript
Avantor, Inc. (NYSE:AVTR ) Q4 2024 Earnings Conference Call February 7, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications Michael Stubblefield - President and CEO Brent Jones - EVP and CFO Conference Call Participants Vijay Kumar - Evercore ISI Michael Ryskin - Bank of America Daniel Brennan - TD Cowen Rachel Vatnsdal - JP Morgan Tycho Peterson - Jefferies Luke Sergott - Barclays Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Conor McNamara - RBC Capital Markets Ivy Ma - Goldman Sachs Brandon Couillard - Wells Fargo Jack Meehan - Nephron Research Operator Hello everybody and a warm welcome to Avantor's Fourth Quarter 2024 Earnings Call. My name is Emily and I'll be coordinating your call today.
Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Avantor (AVTR) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avantor® Reports Fourth Quarter and Full Year 2024 Results
Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1% Net income of $500.4 million; Adjusted EBITDA of $307.7 million Diluted GAAP EPS of $0.73; adjusted EPS of $0.27 Operating cash flow of $173.3 million; free cash flow of $222.1 million Full Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2% Net income of $711.5 million; Adjusted EBITDA of $1,198.8 million Diluted GAAP EPS of $1.04; adjusted EPS of $0.99 Operating cash flow of $840.8 million; free cash flow of $768.3 million RADNOR, Pa. , Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its fourth fiscal quarter and year ended December 31, 2024.
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has partnered with, Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, to expand availability of its innovative nucleic acid products to customers across Europe, Middle East, and Africa (EMEA). This distribution pa.
Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025
RADNOR, Pa. , Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m.
Avantor® to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
RADNOR, Pa. , Jan. 3, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will present at the 43rd Annual J.P.
Avantor: Durable FCF Generator Trading For Cheap
Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor's leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company's capital structure and return value to shareholders.
Avantor® to Participate in the 7th Annual Evercore ISI HealthCONx Conference
RADNOR, Pa. , Nov. 20, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Tuesday, December 3, at 9:10 a.m.
Avantor to Distribute Quantum-Si's Next-Generation Protein Sequencing™ Technology
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in t.
Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science's Biggest Challenges
RADNOR, Pa. , Nov. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center.
Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors
RADNOR, Pa. , Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D.
Avantor Inc. (AVTR) Q3 2024 Earnings Call Transcript
Avantor Inc. (NYSE:AVTR ) Q3 2024 Earnings Conference Call October 25, 2024 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President and Chief Executive Officer Brent Jones - Executive Vice President and Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Douglas Schenkel - Wolfe Research Tycho Peterson - Jefferies Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Daniel Leonard - UBS Conor McNamara - RBC Capital Markets Daniel Arias - Stifel Rachel Vatnsdal - JP Morgan Luke Sergott - Barclays Tejas Savant - Morgan Stanley Operator Good morning. My name is Emily, and I will be your conference operator today.
Avantor (AVTR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Avantor (AVTR) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Avantor® Reports Third Quarter 2024 Results
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 million Diluted GAAP EPS of $0.08; adjusted EPS of $0.26 Operating cash flow of $244.8 million; free cash flow of $204.0 million RADNOR, Pa. , Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for AVTR.